Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Decision Curves and Relative Utility Curves.

Baker SG.

Med Decis Making. 2019 May 20:272989X19850762. doi: 10.1177/0272989X19850762. [Epub ahead of print] No abstract available.

PMID:
31104590
2.

Deriving Real-World Insights From Real-World Data.

Baker SG.

Ann Intern Med. 2019 May 7;170(9):664-665. doi: 10.7326/L19-0084. No abstract available.

PMID:
31060070
3.
4.

Correction to "Latent class instrumental variables: A clinical and biostatistical perspective".

Baker SG, Kramer BS, Lindeman KS.

Stat Med. 2019 Feb 28;38(5):901. doi: 10.1002/sim.8035. Epub 2018 Oct 30. No abstract available.

PMID:
30761594
5.

Cancer Screening Markers: A Simple Strategy to Substantially Reduce the Sample Size for Validation.

Baker SG.

Med Decis Making. 2019 Feb;39(2):130-136. doi: 10.1177/0272989X18819792. Epub 2019 Jan 18.

PMID:
30658540
6.

Early Development of Value of Information Methods.

Baker SG.

Med Decis Making. 2018 Nov;38(8):903. doi: 10.1177/0272989X18809372. No abstract available.

PMID:
30403581
7.

A bias for action in cancer screening?

Scherer LD, Valentine KD, Patel N, Baker SG, Fagerlin A.

J Exp Psychol Appl. 2019 Jun;25(2):149-161. doi: 10.1037/xap0000177. Epub 2018 Jul 19.

PMID:
30024212
8.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Baker SG.

Ann Intern Med. 2018 Apr 17;168(8):606-607. doi: 10.7326/L17-0736. No abstract available.

PMID:
29677260
9.

Hereditary angio-oedema in the Western Cape Province, South Africa.

Coovadia KM, Chothia MY, Baker SG, Peter JG, Potter PC.

S Afr Med J. 2018 Mar 28;108(4):283-290. doi: 10.7196/SAMJ.2017.v108i4.12823.

10.

Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials.

Baker SG.

Stat Med. 2018 Apr 15;37(8):1406. doi: 10.1002/sim.7603. Epub 2018 Jan 22. No abstract available.

PMID:
29529710
11.

Validation of Biomarkers for Early Detection of Pancreatic Cancer: Summary of The Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection Workshop.

Young MR, Wagner PD, Ghosh S, Rinaudo JA, Baker SG, Zaret KS, Goggins M, Srivastava S.

Pancreas. 2018 Feb;47(2):135-141. doi: 10.1097/MPA.0000000000000973.

12.

A 23-year retrospective investigation of Salmonella Typhi and Salmonella Paratyphi isolated in a tertiary Kathmandu hospital.

Zellweger RM, Basnyat B, Shrestha P, Prajapati KG, Dongol S, Sharma PK, Koirala S, Darton TC, Dolecek C, Thompson CN, Thwaites GE, Baker SG, Karkey A.

PLoS Negl Trop Dis. 2017 Nov 27;11(11):e0006051. doi: 10.1371/journal.pntd.0006051. eCollection 2017 Nov.

13.
14.

The summary test tradeoff: a new measure of the value of an additional risk prediction marker.

Baker SG.

Stat Med. 2017 Dec 10;36(28):4491-4494. doi: 10.1002/sim.7132. No abstract available.

15.

Editorial: Challenges in Quantifying Overdiagnosis.

Baker SG, Prorok PC, Kramer BS.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx064. No abstract available.

16.

Simple Decision-Analytic Functions of the AUC for Ruling Out a Risk Prediction Model and an Added Predictor.

Baker SG.

Med Decis Making. 2018 Feb;38(2):225-234. doi: 10.1177/0272989X17732994. Epub 2017 Oct 12.

17.

The Influence of Effortful Thought and Cognitive Proficiencies on the Conjunction Fallacy: Implications for Dual-Process Theories of Reasoning and Judgment.

Scherer LD, Yates JF, Baker SG, Valentine KD.

Pers Soc Psychol Bull. 2017 Jun;43(6):874-887. doi: 10.1177/0146167217700607. Epub 2017 Apr 20.

PMID:
28903676
18.

Validity of Surrogate End Points for Prostate Cancer.

Baker SG.

JAMA Oncol. 2018 Jan 1;4(1):129-130. doi: 10.1001/jamaoncol.2017.0334. No abstract available.

PMID:
28859193
19.

Instrumental variable meta-analysis Comment on: Adjustment for compliance behavior in trials of epidural analgesia in labor using instrumental variable meta-analysis.

Baker SG, Lindeman KS.

J Clin Epidemiol. 2017 Nov;91:146-147. doi: 10.1016/j.jclinepi.2017.07.013. Epub 2017 Aug 9. No abstract available.

PMID:
28802676
20.

The effect of mood on judgments of subjective well-being: Nine tests of the judgment model.

Yap SCY, Wortman J, Anusic I, Baker SG, Scherer LD, Donnellan MB, Lucas RE.

J Pers Soc Psychol. 2017 Dec;113(6):939-961. doi: 10.1037/pspp0000115. Epub 2016 Dec 12.

21.

Evaluating Markers for Guiding Treatment.

Baker SG, Bonetti M.

J Natl Cancer Inst. 2016 May 18;108(9). pii: djw101. doi: 10.1093/jnci/djw101. Print 2016 Sep.

22.

The latent class twin method.

Baker SG.

Biometrics. 2016 Sep;72(3):827-34. doi: 10.1111/biom.12460. Epub 2016 Jan 11.

23.

RE: Leveraging Biospecimen Resources for Discovery or Validation of Markers for Early Cancer Detection.

Baker SG.

J Natl Cancer Inst. 2015 Sep;107(9). doi: 10.1093/jnci/djv215. No abstract available.

24.

Latent class instrumental variables: a clinical and biostatistical perspective.

Baker SG, Kramer BS, Lindeman KS.

Stat Med. 2016 Jan 15;35(1):147-60. doi: 10.1002/sim.6612. Epub 2015 Aug 4. Erratum in: Stat Med. 2019 Feb 28;38(5):901.

25.

Evaluating Prognostic Markers Using Relative Utility Curves and Test Tradeoffs.

Baker SG, Kramer BS.

J Clin Oncol. 2015 Aug 10;33(23):2578-80. doi: 10.1200/JCO.2014.58.0092. Epub 2015 Jun 29. No abstract available.

27.

Re: Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer.

Baker SG.

J Natl Cancer Inst. 2015 May 7;107(6):djv127. doi: 10.1093/jnci/djv127. Print 2015 Jun. No abstract available.

28.

Response.

Baker SG.

J Natl Cancer Inst. 2015 Mar 11;107(5). pii: djv061. doi: 10.1093/jnci/djv061. No abstract available.

29.

A cancer theory kerfuffle can lead to new lines of research.

Baker SG.

J Natl Cancer Inst. 2014 Dec 20;107(2). pii: dju405. doi: 10.1093/jnci/dju405. Print 2015 Feb.

30.

Instrumental variable analyses for observational comparative effectiveness research: the paired availability design.

Baker SG, Lindeman KS.

Ann Intern Med. 2014 Dec 2;161(11):840-1. doi: 10.7326/L14-5029. No abstract available.

PMID:
25437417
31.

Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes.

Baker SG, Kramer BS.

Clin Trials. 2015 Aug;12(4):299-308. doi: 10.1177/1740774514557725. Epub 2014 Nov 10.

32.

Lead time and overdiagnosis.

Baker SG, Prorok PC, Kramer BS.

J Natl Cancer Inst. 2014 Oct 31;106(12). pii: dju346. doi: 10.1093/jnci/dju346. Print 2014 Dec. No abstract available. Erratum in: J Natl Cancer Inst. J Natl Cancer Inst. 2015 Mar;107(3):doi/10.1093/jnci/djv019.

PMID:
25362702
33.

A latent class method for diagnostic tests: the new, reference, gold standard problem.

Baker SG.

Stat Med. 2014 Oct 30;33(24):4320. doi: 10.1002/sim.6283. No abstract available.

34.

Biomarker evaluation in randomized trials: addressing different research questions.

Baker SG.

Stat Med. 2014 Oct 15;33(23):4139-40. doi: 10.1002/sim.6202. No abstract available.

35.

Instrumental variable methods for causal inference: early work and recent developments.

Baker SG.

Stat Med. 2014 Jul 30;33(17):3058-9. doi: 10.1002/sim.6168. No abstract available.

PMID:
24989339
36.

Principal stratification: All-or-none versus partial compliance.

Baker SG.

Clin Trials. 2014 Jun;11(3):380-381. doi: 10.1177/1740774514524650. No abstract available.

37.

How to interpret a small increase in AUC with an additional risk prediction marker: decision analysis comes through.

Baker SG, Schuit E, Steyerberg EW, Pencina MJ, Vickers A, Moons KG, Mol BW, Lindeman KS.

Stat Med. 2014 Sep 28;33(22):3946-59. doi: 10.1002/sim.6195. Epub 2014 May 13. Erratum in: Stat Med. 2014 Feb 28;34(5):900. Vickers, Andew [corrected to Vickers, Andrew]. Stat Med. 2014 Sep 28;33(22)3960.

38.

The randomized registry trial.

Baker SG, Kramer BS, Lindeman KS.

N Engl J Med. 2014 Feb 13;370(7):681-2. doi: 10.1056/NEJMc1315677. No abstract available.

PMID:
24521130
39.
40.
41.

Additional thoughts on causal inference, probability theory, and graphical insights.

Baker SG.

Stat Med. 2013 Nov 10;32(25):4334-7. No abstract available.

42.

Causal inference, probability theory, and graphical insights.

Baker SG.

Stat Med. 2013 Nov 10;32(25):4319-30. doi: 10.1002/sim.5828. Epub 2013 May 10. Erratum in: Stat Med. 2014 May 20;33(11):1980.

43.

The risky reliance on small surrogate endpoint studies when planning a large prevention trial.

Baker SG, Kramer BS.

J R Stat Soc Ser A Stat Soc. 2013 Feb 1;176(2):603-608. Epub 2012 Jun 28.

44.

Combination antifungal therapy for cryptococcal meningitis.

Day JN, Chau TTH, Wolbers M, Mai PP, Dung NT, Mai NH, Phu NH, Nghia HD, Phong ND, Thai CQ, Thai LH, Chuong LV, Sinh DX, Duong VA, Hoang TN, Diep PT, Campbell JI, Sieu TPM, Baker SG, Chau NVV, Hien TT, Lalloo DG, Farrar JJ.

N Engl J Med. 2013 Apr 4;368(14):1291-1302. doi: 10.1056/NEJMoa1110404.

45.

Remarks on 'A simple decision analytic solution to the comparison of two binary diagnostic tests' by Vickers et al.

Baker SG.

Stat Med. 2013 Feb 20;32(4):718. doi: 10.1002/sim.5663. No abstract available.

46.

Evaluation of markers and risk prediction models: overview of relationships between NRI and decision-analytic measures.

Van Calster B, Vickers AJ, Pencina MJ, Baker SG, Timmerman D, Steyerberg EW.

Med Decis Making. 2013 May;33(4):490-501. doi: 10.1177/0272989X12470757. Epub 2013 Jan 11. Review.

47.

A Rapid, Multiplexed, High-Throughput Flow-Through Membrane Immunoassay: A Convenient Alternative to ELISA.

Ramachandran S, Singhal M, McKenzie KG, Osborn JL, Arjyal A, Dongol S, Baker SG, Basnyat B, Farrar J, Dolecek C, Domingo GJ, Yager P, Lutz B.

Diagnostics (Basel). 2013 Apr 2;3(2):244-60. doi: 10.3390/diagnostics3020244.

48.

Surrogate endpoint analysis: an exercise in extrapolation.

Baker SG, Kramer BS.

J Natl Cancer Inst. 2013 Mar 6;105(5):316-20. doi: 10.1093/jnci/djs527. Epub 2012 Dec 21.

49.

Clonality despite sex: the evolution of host-associated sexual neighborhoods in the pathogenic fungus Penicillium marneffei.

Henk DA, Shahar-Golan R, Devi KR, Boyce KJ, Zhan N, Fedorova ND, Nierman WC, Hsueh PR, Yuen KY, Sieu TP, Kinh NV, Wertheim H, Baker SG, Day JN, Vanittanakom N, Bignell EM, Andrianopoulos A, Fisher MC.

PLoS Pathog. 2012;8(10):e1002851. doi: 10.1371/journal.ppat.1002851. Epub 2012 Oct 4.

50.

Evaluating a new marker for risk prediction: decision analysis to the rescue.

Baker SG, Kramer BS.

Discov Med. 2012 Sep;14(76):181-8. Review.

Supplemental Content

Loading ...
Support Center